Trevi Therapeutics Inc (NASDAQ: TRVI) on Tuesday, soared 3.28% from the previous trading day, before settling in for the closing price of $6.40. Within the past 52 weeks, TRVI’s price has moved between $2.30 and $7.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -11.80%. With a float of $57.14 million, this company’s outstanding shares have now reached $93.60 million.
In an organization with 26 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Trevi Therapeutics Inc is 40.90%, while institutional ownership is 45.56%. The most recent insider transaction that took place on Mar 21 ’25, was worth 34,625. In this transaction President & CEO of this company sold 5,263 shares at a rate of $6.58, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Officer proposed sale 5,263 for $6.58, making the entire transaction worth $34,625.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.10% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Trevi Therapeutics Inc (TRVI) is currently performing well based on its current performance indicators. A quick ratio of 10.41 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.75 million. That was inferior than the volume of 2.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.30%. Additionally, its Average True Range was 0.47.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 84.49%, which indicates a significant increase from 75.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 144.99% in the past 14 days, which was higher than the 101.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.70, while its 200-day Moving Average is $3.49. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $6.81. Second resistance stands at $7.00. The third major resistance level sits at $7.22. If the price goes on to break the first support level at $6.39, it is likely to go to the next support level at $6.17. Assuming the price breaks the second support level, the third support level stands at $5.98.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
Market capitalization of the company is 639.07 million based on 96,682K outstanding shares. Right now, sales total 0 K and income totals -47,910 K. The company made 0 K in profit during its latest quarter, and -11,420 K in sales during its previous quarter.
